Dr. Richard Brown -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Richard Brown, a Cardiology physician based in Fort Lauderdale, FL. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Richard Brown has received $4,117.04 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Richard Brown has received a total of $4,117.04 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $4,117.04 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Richard Brown's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Travel & Lodging$4,117.04Transportation and hotel expenses for conferences and meetings

The largest payment category for Dr. Richard Brown is Travel & Lodging, accounting for 100% ($4,117.04) of total pharmaceutical payments received. This represents the primary type of financial relationship between Dr. Richard Brown and pharmaceutical companies.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Richard Brown. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
Amgen Inc$4,117.041

Dr. Richard Brown has a financial relationship with Amgen Inc, receiving $4,117.04 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Richard Brown's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Richard Brown has received $4.1K across 1 pharmaceutical payments as a Cardiology physician in Fort Lauderdale, FL. Top paying companies include Amgen Inc ($4.1K). Dr. Brown received a single payment of $4,117 in 2024, which was for travel expenses. The entire payment amount came from Amgen Inc., indicating a high concentration from a single manufacturer. With only one payment recorded, the data provides a limited snapshot of his overall payment profile.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Richard Brown is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

Patients may wish to inquire about any potential influence of pharmaceutical payments on their physician's treatment recommendations, especially when a physician has received significant payments from a single company. Always feel free to ask your doctor directly about their pharmaceutical relationships.

Peer Comparison: How Dr. Richard Brown Compares to Other Cardiology Physicians

As a cardiologist, Dr. Brown's payment profile is less common, with a single large travel payment from one company, unlike many peers who may receive multiple smaller payments for consulting or speaking engagements.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Richard Brown in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
Amgen Inc$4,117.04travelN/A2024-10-19Not Assessed

Frequently Asked Questions About Dr. Richard Brown's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much pharma money has Richard Brown received?

Richard Brown has received a total of $4.1K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.

Is Richard Brown taking too much pharma money?

Richard Brown has received $4.1K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Cardiology), the types of payments, and how they compare to peers. The largest payment category is travel ($4.1K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.

What pharma companies pay Richard Brown?

The top pharmaceutical companies paying Richard Brown are: Amgen Inc ($4.1K). These payments cover various categories including consulting, meals, speaking fees, and research grants.

What kinds of payments does Richard Brown receive?

Richard Brown's payments by type: travel: $4.1K.

Should I switch doctors because of pharma payments?

Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.

How do Richard Brown's payments compare to other Cardiology doctors?

To compare, look at the total amount ($4.1K), number of payments (1), and the types of payments received. Cardiology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.

How can I verify Richard Brown's payment data?

You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1252980897). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.

Do pharma payments affect prescribing quality?

Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.

What stands out about Richard Brown's pharma payment profile?

The sole payment received by Dr. Brown was categorized as 'travel'. Richard Brown has received $4.1K in total pharma payments.

How does Richard Brown compare to peers in Cardiology?

As a cardiologist, Dr. Brown's payment profile is less common, with a single large travel payment from one company, unlike many peers who may receive multiple smaller payments for consulting or speaking engagements.

Are Richard Brown's pharma relationships typical for Cardiology?

The payment was made by Amgen Inc., a significant player in the pharmaceutical industry.

What should patients of Richard Brown know about these payments?

Patients may wish to inquire about any potential influence of pharmaceutical payments on their physician's treatment recommendations, especially when a physician has received significant payments from a single company.

What patterns are visible in Richard Brown's payment history?

The total amount received is relatively high for a single payment, suggesting it may cover a substantial travel-related event or expense.

Understanding This Doctor Payment Report

This transparency report for Dr. Richard Brown is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Richard Brown's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Richard Brown and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.